nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—ABCB1—peripheral nervous system neoplasm	0.124	1	CbGaD
Dasatinib—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0388	0.107	CbGbCtD
Dasatinib—CYP1A1—Tretinoin—peripheral nervous system neoplasm	0.0333	0.0917	CbGbCtD
Dasatinib—CYP1A1—Dacarbazine—peripheral nervous system neoplasm	0.0286	0.0788	CbGbCtD
Dasatinib—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0269	0.074	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—peripheral nervous system neoplasm	0.0218	0.0599	CbGbCtD
Dasatinib—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.02	0.055	CbGbCtD
Dasatinib—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0166	0.0456	CbGbCtD
Dasatinib—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.016	0.044	CbGbCtD
Dasatinib—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0154	0.0425	CbGbCtD
Dasatinib—ABCG2—Etoposide—peripheral nervous system neoplasm	0.0152	0.0418	CbGbCtD
Dasatinib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.014	0.0385	CbGbCtD
Dasatinib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.014	0.0385	CbGbCtD
Dasatinib—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0128	0.0352	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.0103	0.0285	CbGbCtD
Dasatinib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0097	0.0267	CbGbCtD
Dasatinib—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.00917	0.0253	CbGbCtD
Dasatinib—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.00841	0.0231	CbGbCtD
Dasatinib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.00838	0.0231	CbGbCtD
Dasatinib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00779	0.0215	CbGbCtD
Dasatinib—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.00626	0.0172	CbGbCtD
Dasatinib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00597	0.0164	CbGbCtD
Dasatinib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00557	0.0153	CbGbCtD
Dasatinib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00547	0.0151	CbGbCtD
Dasatinib—EPHB1—tongue—peripheral nervous system neoplasm	0.00376	0.0601	CbGeAlD
Dasatinib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00373	0.0103	CbGbCtD
Dasatinib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00358	0.00985	CbGbCtD
Dasatinib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00328	0.00903	CbGbCtD
Dasatinib—EPHB2—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.00237	0.499	CbGdCrCtD
Dasatinib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00224	0.00616	CbGbCtD
Dasatinib—EPHB3—nerve—peripheral nervous system neoplasm	0.00208	0.0333	CbGeAlD
Dasatinib—EPHA4—nerve—peripheral nervous system neoplasm	0.00174	0.0278	CbGeAlD
Dasatinib—EPHA4—ganglion—peripheral nervous system neoplasm	0.00172	0.0275	CbGeAlD
Dasatinib—EPHA4—tongue—peripheral nervous system neoplasm	0.0017	0.0272	CbGeAlD
Dasatinib—EPHB2—brainstem—peripheral nervous system neoplasm	0.00136	0.0217	CbGeAlD
Dasatinib—STAT5B—brainstem—peripheral nervous system neoplasm	0.00123	0.0197	CbGeAlD
Dasatinib—MYT1—cerebellum—peripheral nervous system neoplasm	0.00122	0.0195	CbGeAlD
Dasatinib—EPHA5—trigeminal ganglion—peripheral nervous system neoplasm	0.00114	0.0182	CbGeAlD
Dasatinib—BTK—trigeminal ganglion—peripheral nervous system neoplasm	0.00111	0.0177	CbGeAlD
Dasatinib—TESK1—trigeminal ganglion—peripheral nervous system neoplasm	0.00103	0.0164	CbGeAlD
Dasatinib—EPHB3—trigeminal ganglion—peripheral nervous system neoplasm	0.00101	0.0162	CbGeAlD
Dasatinib—TESK1—parotid gland—peripheral nervous system neoplasm	0.000968	0.0155	CbGeAlD
Dasatinib—CSK—trigeminal ganglion—peripheral nervous system neoplasm	0.00094	0.015	CbGeAlD
Dasatinib—HCK—trigeminal ganglion—peripheral nervous system neoplasm	0.000928	0.0149	CbGeAlD
Dasatinib—EPHB3—brainstem—peripheral nervous system neoplasm	0.000894	0.0143	CbGeAlD
Dasatinib—CSK—parotid gland—peripheral nervous system neoplasm	0.000887	0.0142	CbGeAlD
Dasatinib—RIPK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000873	0.014	CbGeAlD
Dasatinib—SIK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000852	0.0136	CbGeAlD
Dasatinib—STK35—brainstem—peripheral nervous system neoplasm	0.000838	0.0134	CbGeAlD
Dasatinib—RIPK2—parotid gland—peripheral nervous system neoplasm	0.000823	0.0132	CbGeAlD
Dasatinib—EPHB1—cerebellum—peripheral nervous system neoplasm	0.000814	0.013	CbGeAlD
Dasatinib—SIK1—parotid gland—peripheral nervous system neoplasm	0.000804	0.0129	CbGeAlD
Dasatinib—LCK—trigeminal ganglion—peripheral nervous system neoplasm	0.000775	0.0124	CbGeAlD
Dasatinib—EPHA4—brainstem—peripheral nervous system neoplasm	0.000747	0.0119	CbGeAlD
Dasatinib—EPHB4—trigeminal ganglion—peripheral nervous system neoplasm	0.000737	0.0118	CbGeAlD
Dasatinib—JAK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000732	0.0117	CbGeAlD
Dasatinib—EPHA2—trigeminal ganglion—peripheral nervous system neoplasm	0.000723	0.0116	CbGeAlD
Dasatinib—FYN—trigeminal ganglion—peripheral nervous system neoplasm	0.000722	0.0116	CbGeAlD
Dasatinib—MAP3K3—trigeminal ganglion—peripheral nervous system neoplasm	0.000706	0.0113	CbGeAlD
Dasatinib—MAP4K5—trigeminal ganglion—peripheral nervous system neoplasm	0.000706	0.0113	CbGeAlD
Dasatinib—FMO3—parotid gland—peripheral nervous system neoplasm	0.000706	0.0113	CbGeAlD
Dasatinib—PKMYT1—cerebellum—peripheral nervous system neoplasm	0.000701	0.0112	CbGeAlD
Dasatinib—EPHB4—parotid gland—peripheral nervous system neoplasm	0.000696	0.0111	CbGeAlD
Dasatinib—MAPK14—brainstem—peripheral nervous system neoplasm	0.000688	0.011	CbGeAlD
Dasatinib—EPHA2—parotid gland—peripheral nervous system neoplasm	0.000682	0.0109	CbGeAlD
Dasatinib—EPHB6—trigeminal ganglion—peripheral nervous system neoplasm	0.000674	0.0108	CbGeAlD
Dasatinib—MAP3K3—parotid gland—peripheral nervous system neoplasm	0.000666	0.0107	CbGeAlD
Dasatinib—MAP4K5—parotid gland—peripheral nervous system neoplasm	0.000666	0.0107	CbGeAlD
Dasatinib—YES1—trigeminal ganglion—peripheral nervous system neoplasm	0.000652	0.0104	CbGeAlD
Dasatinib—EPHA8—cerebellum—peripheral nervous system neoplasm	0.000641	0.0103	CbGeAlD
Dasatinib—FYN—brainstem—peripheral nervous system neoplasm	0.000639	0.0102	CbGeAlD
Dasatinib—EPHB6—parotid gland—peripheral nervous system neoplasm	0.000636	0.0102	CbGeAlD
Dasatinib—YES1—parotid gland—peripheral nervous system neoplasm	0.000615	0.00984	CbGeAlD
Dasatinib—STAT5B—cerebellum—peripheral nervous system neoplasm	0.000606	0.0097	CbGeAlD
Dasatinib—MAP2K5—trigeminal ganglion—peripheral nervous system neoplasm	0.000577	0.00923	CbGeAlD
Dasatinib—CSF1R—trigeminal ganglion—peripheral nervous system neoplasm	0.000563	0.00901	CbGeAlD
Dasatinib—SIK3—cerebellum—peripheral nervous system neoplasm	0.000545	0.00872	CbGeAlD
Dasatinib—MAP2K5—parotid gland—peripheral nervous system neoplasm	0.000544	0.00871	CbGeAlD
Dasatinib—KIT—trigeminal ganglion—peripheral nervous system neoplasm	0.000511	0.00818	CbGeAlD
Dasatinib—MAP2K5—brainstem—peripheral nervous system neoplasm	0.00051	0.00817	CbGeAlD
Dasatinib—ZAK—cerebellum—peripheral nervous system neoplasm	0.000507	0.00811	CbGeAlD
Dasatinib—PDGFRB—trigeminal ganglion—peripheral nervous system neoplasm	0.000499	0.00799	CbGeAlD
Dasatinib—EPHA5—cerebellum—peripheral nervous system neoplasm	0.000496	0.00793	CbGeAlD
Dasatinib—BMPR1B—cerebellum—peripheral nervous system neoplasm	0.000486	0.00777	CbGeAlD
Dasatinib—KIT—parotid gland—peripheral nervous system neoplasm	0.000482	0.00772	CbGeAlD
Dasatinib—TNK2—cerebellum—peripheral nervous system neoplasm	0.000476	0.00762	CbGeAlD
Dasatinib—PDGFRB—parotid gland—peripheral nervous system neoplasm	0.000471	0.00754	CbGeAlD
Dasatinib—KIT—brainstem—peripheral nervous system neoplasm	0.000452	0.00724	CbGeAlD
Dasatinib—TESK1—cerebellum—peripheral nervous system neoplasm	0.000448	0.00717	CbGeAlD
Dasatinib—ABL1—trigeminal ganglion—peripheral nervous system neoplasm	0.000445	0.00712	CbGeAlD
Dasatinib—STK36—cerebellum—peripheral nervous system neoplasm	0.000441	0.00705	CbGeAlD
Dasatinib—EPHB3—cerebellum—peripheral nervous system neoplasm	0.000441	0.00705	CbGeAlD
Dasatinib—ERBB3—Podofilox—Etoposide—peripheral nervous system neoplasm	0.000433	0.0913	CbGdCrCtD
Dasatinib—LIMK2—cerebellum—peripheral nervous system neoplasm	0.000426	0.00682	CbGeAlD
Dasatinib—ABL1—parotid gland—peripheral nervous system neoplasm	0.00042	0.00672	CbGeAlD
Dasatinib—STK35—cerebellum—peripheral nervous system neoplasm	0.000413	0.00661	CbGeAlD
Dasatinib—CSK—cerebellum—peripheral nervous system neoplasm	0.00041	0.00657	CbGeAlD
Dasatinib—ABL2—cerebellum—peripheral nervous system neoplasm	0.000402	0.00644	CbGeAlD
Dasatinib—ABL1—brainstem—peripheral nervous system neoplasm	0.000394	0.0063	CbGeAlD
Dasatinib—RIPK2—cerebellum—peripheral nervous system neoplasm	0.000381	0.00609	CbGeAlD
Dasatinib—SIK1—cerebellum—peripheral nervous system neoplasm	0.000372	0.00595	CbGeAlD
Dasatinib—EPHA4—cerebellum—peripheral nervous system neoplasm	0.000368	0.00589	CbGeAlD
Dasatinib—ERBB3—cerebellum—peripheral nervous system neoplasm	0.000364	0.00583	CbGeAlD
Dasatinib—MAP3K2—cerebellum—peripheral nervous system neoplasm	0.000361	0.00578	CbGeAlD
Dasatinib—MAPK14—cerebellum—peripheral nervous system neoplasm	0.000339	0.00543	CbGeAlD
Dasatinib—EPHB4—cerebellum—peripheral nervous system neoplasm	0.000322	0.00515	CbGeAlD
Dasatinib—JAK2—cerebellum—peripheral nervous system neoplasm	0.000319	0.00511	CbGeAlD
Dasatinib—FYN—cerebellum—peripheral nervous system neoplasm	0.000315	0.00504	CbGeAlD
Dasatinib—MAP3K3—cerebellum—peripheral nervous system neoplasm	0.000308	0.00493	CbGeAlD
Dasatinib—MAP4K5—cerebellum—peripheral nervous system neoplasm	0.000308	0.00493	CbGeAlD
Dasatinib—ERBB3—Vinblastine—Vincristine—peripheral nervous system neoplasm	0.000298	0.0628	CbGdCrCtD
Dasatinib—EPHB6—cerebellum—peripheral nervous system neoplasm	0.000294	0.00471	CbGeAlD
Dasatinib—YES1—cerebellum—peripheral nervous system neoplasm	0.000284	0.00455	CbGeAlD
Dasatinib—ABCG2—trigeminal ganglion—peripheral nervous system neoplasm	0.000281	0.00449	CbGeAlD
Dasatinib—PDGFRA—cerebellum—peripheral nervous system neoplasm	0.000279	0.00446	CbGeAlD
Dasatinib—SRC—cerebellum—peripheral nervous system neoplasm	0.000274	0.00438	CbGeAlD
Dasatinib—ABCG2—parotid gland—peripheral nervous system neoplasm	0.000265	0.00424	CbGeAlD
Dasatinib—MAP2K5—cerebellum—peripheral nervous system neoplasm	0.000252	0.00403	CbGeAlD
Dasatinib—CYP1A1—parotid gland—peripheral nervous system neoplasm	0.000251	0.00402	CbGeAlD
Dasatinib—CSF1R—cerebellum—peripheral nervous system neoplasm	0.000246	0.00393	CbGeAlD
Dasatinib—KIT—cerebellum—peripheral nervous system neoplasm	0.000223	0.00357	CbGeAlD
Dasatinib—PDGFRB—cerebellum—peripheral nervous system neoplasm	0.000218	0.00349	CbGeAlD
Dasatinib—CSK—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000208	0.044	CbGdCrCtD
Dasatinib—CSK—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000208	0.044	CbGdCrCtD
Dasatinib—ABL1—cerebellum—peripheral nervous system neoplasm	0.000194	0.00311	CbGeAlD
Dasatinib—CSK—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.0407	CbGdCrCtD
Dasatinib—CSK—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.0407	CbGdCrCtD
Dasatinib—CYP1B1—cerebellum—peripheral nervous system neoplasm	0.000164	0.00263	CbGeAlD
Dasatinib—ABL1—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000146	0.0307	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000146	0.0307	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000146	0.0307	CbGdCrCtD
Dasatinib—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000138	0.00221	CbGeAlD
Dasatinib—ABL1—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.0284	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.0284	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.0284	CbGdCrCtD
Dasatinib—ABCG2—cerebellum—peripheral nervous system neoplasm	0.000122	0.00196	CbGeAlD
Dasatinib—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	7.11e-05	0.000291	CcSEcCtD
Dasatinib—Hypotension—Etoposide—peripheral nervous system neoplasm	7.09e-05	0.000291	CcSEcCtD
Dasatinib—Gastritis—Doxorubicin—peripheral nervous system neoplasm	7.09e-05	0.000291	CcSEcCtD
Dasatinib—Pain—Cisplatin—peripheral nervous system neoplasm	7.09e-05	0.00029	CcSEcCtD
Dasatinib—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	7.07e-05	0.00029	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	7.07e-05	0.00029	CcSEcCtD
Dasatinib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	7e-05	0.000287	CcSEcCtD
Dasatinib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	6.98e-05	0.000286	CcSEcCtD
Dasatinib—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	6.97e-05	0.000286	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	6.95e-05	0.000285	CcSEcCtD
Dasatinib—Asthma—Doxorubicin—peripheral nervous system neoplasm	6.92e-05	0.000284	CcSEcCtD
Dasatinib—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	6.92e-05	0.000284	CcSEcCtD
Dasatinib—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	6.91e-05	0.000283	CcSEcCtD
Dasatinib—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	6.9e-05	0.000283	CcSEcCtD
Dasatinib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	6.88e-05	0.000282	CcSEcCtD
Dasatinib—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	6.83e-05	0.00028	CcSEcCtD
Dasatinib—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	6.83e-05	0.00028	CcSEcCtD
Dasatinib—Weight increased—Epirubicin—peripheral nervous system neoplasm	6.81e-05	0.000279	CcSEcCtD
Dasatinib—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	6.79e-05	0.000278	CcSEcCtD
Dasatinib—Weight decreased—Epirubicin—peripheral nervous system neoplasm	6.77e-05	0.000277	CcSEcCtD
Dasatinib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	6.77e-05	0.000277	CcSEcCtD
Dasatinib—Somnolence—Etoposide—peripheral nervous system neoplasm	6.75e-05	0.000277	CcSEcCtD
Dasatinib—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	6.74e-05	0.000276	CcSEcCtD
Dasatinib—Asthenia—Vincristine—peripheral nervous system neoplasm	6.72e-05	0.000276	CcSEcCtD
Dasatinib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	6.71e-05	0.000275	CcSEcCtD
Dasatinib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	6.67e-05	0.000273	CcSEcCtD
Dasatinib—Infestation—Epirubicin—peripheral nervous system neoplasm	6.67e-05	0.000273	CcSEcCtD
Dasatinib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	6.67e-05	0.000273	CcSEcCtD
Dasatinib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	6.65e-05	0.000273	CcSEcCtD
Dasatinib—Rash—Dactinomycin—peripheral nervous system neoplasm	6.61e-05	0.000271	CcSEcCtD
Dasatinib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	6.6e-05	0.00027	CcSEcCtD
Dasatinib—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	6.57e-05	0.000269	CcSEcCtD
Dasatinib—Renal failure—Epirubicin—peripheral nervous system neoplasm	6.56e-05	0.000269	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	6.55e-05	0.000269	CcSEcCtD
Dasatinib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	6.55e-05	0.000268	CcSEcCtD
Dasatinib—Fatigue—Etoposide—peripheral nervous system neoplasm	6.54e-05	0.000268	CcSEcCtD
Dasatinib—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	6.54e-05	0.000268	CcSEcCtD
Dasatinib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	6.5e-05	0.000267	CcSEcCtD
Dasatinib—Constipation—Etoposide—peripheral nervous system neoplasm	6.49e-05	0.000266	CcSEcCtD
Dasatinib—Pain—Etoposide—peripheral nervous system neoplasm	6.49e-05	0.000266	CcSEcCtD
Dasatinib—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	6.48e-05	0.000266	CcSEcCtD
Dasatinib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	6.47e-05	0.000265	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	6.43e-05	0.000264	CcSEcCtD
Dasatinib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	6.43e-05	0.000264	CcSEcCtD
Dasatinib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	6.41e-05	0.000263	CcSEcCtD
Dasatinib—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	6.4e-05	0.000262	CcSEcCtD
Dasatinib—Haematuria—Epirubicin—peripheral nervous system neoplasm	6.36e-05	0.000261	CcSEcCtD
Dasatinib—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	6.32e-05	0.000259	CcSEcCtD
Dasatinib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	6.31e-05	0.000259	CcSEcCtD
Dasatinib—Weight increased—Doxorubicin—peripheral nervous system neoplasm	6.3e-05	0.000258	CcSEcCtD
Dasatinib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	6.29e-05	0.000258	CcSEcCtD
Dasatinib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	6.26e-05	0.000257	CcSEcCtD
Dasatinib—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	6.26e-05	0.000256	CcSEcCtD
Dasatinib—Nausea—Dactinomycin—peripheral nervous system neoplasm	6.23e-05	0.000255	CcSEcCtD
Dasatinib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	6.21e-05	0.000254	CcSEcCtD
Dasatinib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	6.21e-05	0.000254	CcSEcCtD
Dasatinib—Dizziness—Vincristine—peripheral nervous system neoplasm	6.2e-05	0.000254	CcSEcCtD
Dasatinib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	6.18e-05	0.000253	CcSEcCtD
Dasatinib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	6.17e-05	0.000253	CcSEcCtD
Dasatinib—Infestation—Doxorubicin—peripheral nervous system neoplasm	6.17e-05	0.000253	CcSEcCtD
Dasatinib—Rash—Alitretinoin—peripheral nervous system neoplasm	6.13e-05	0.000251	CcSEcCtD
Dasatinib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	6.13e-05	0.000251	CcSEcCtD
Dasatinib—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	6.1e-05	0.00025	CcSEcCtD
Dasatinib—Headache—Alitretinoin—peripheral nervous system neoplasm	6.09e-05	0.00025	CcSEcCtD
Dasatinib—Renal failure—Doxorubicin—peripheral nervous system neoplasm	6.07e-05	0.000249	CcSEcCtD
Dasatinib—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	6.05e-05	0.000248	CcSEcCtD
Dasatinib—ABCB1—cerebellum—peripheral nervous system neoplasm	6.04e-05	0.000966	CbGeAlD
Dasatinib—Urticaria—Etoposide—peripheral nervous system neoplasm	6.03e-05	0.000247	CcSEcCtD
Dasatinib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	6.02e-05	0.000247	CcSEcCtD
Dasatinib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	6.02e-05	0.000247	CcSEcCtD
Dasatinib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	6e-05	0.000246	CcSEcCtD
Dasatinib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	6e-05	0.000246	CcSEcCtD
Dasatinib—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	6e-05	0.000246	CcSEcCtD
Dasatinib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	5.99e-05	0.000245	CcSEcCtD
Dasatinib—Hepatitis—Epirubicin—peripheral nervous system neoplasm	5.99e-05	0.000245	CcSEcCtD
Dasatinib—Vomiting—Vincristine—peripheral nervous system neoplasm	5.96e-05	0.000244	CcSEcCtD
Dasatinib—Asthenia—Cisplatin—peripheral nervous system neoplasm	5.94e-05	0.000244	CcSEcCtD
Dasatinib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	5.91e-05	0.000242	CcSEcCtD
Dasatinib—Rash—Vincristine—peripheral nervous system neoplasm	5.91e-05	0.000242	CcSEcCtD
Dasatinib—Dermatitis—Vincristine—peripheral nervous system neoplasm	5.9e-05	0.000242	CcSEcCtD
Dasatinib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	5.9e-05	0.000242	CcSEcCtD
Dasatinib—Haematuria—Doxorubicin—peripheral nervous system neoplasm	5.89e-05	0.000241	CcSEcCtD
Dasatinib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	5.89e-05	0.000241	CcSEcCtD
Dasatinib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	5.87e-05	0.000241	CcSEcCtD
Dasatinib—Headache—Vincristine—peripheral nervous system neoplasm	5.87e-05	0.000241	CcSEcCtD
Dasatinib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	5.84e-05	0.000239	CcSEcCtD
Dasatinib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	5.82e-05	0.000239	CcSEcCtD
Dasatinib—Nausea—Alitretinoin—peripheral nervous system neoplasm	5.78e-05	0.000237	CcSEcCtD
Dasatinib—Visual impairment—Epirubicin—peripheral nervous system neoplasm	5.77e-05	0.000237	CcSEcCtD
Dasatinib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	5.67e-05	0.000232	CcSEcCtD
Dasatinib—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	5.66e-05	0.000232	CcSEcCtD
Dasatinib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	5.6e-05	0.000229	CcSEcCtD
Dasatinib—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	5.59e-05	0.000229	CcSEcCtD
Dasatinib—Tinnitus—Epirubicin—peripheral nervous system neoplasm	5.58e-05	0.000229	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	5.57e-05	0.000228	CcSEcCtD
Dasatinib—Nausea—Vincristine—peripheral nervous system neoplasm	5.57e-05	0.000228	CcSEcCtD
Dasatinib—Flushing—Epirubicin—peripheral nervous system neoplasm	5.56e-05	0.000228	CcSEcCtD
Dasatinib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	5.56e-05	0.000228	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	5.54e-05	0.000227	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	5.54e-05	0.000227	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	5.47e-05	0.000224	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	5.46e-05	0.000224	CcSEcCtD
Dasatinib—Asthenia—Etoposide—peripheral nervous system neoplasm	5.45e-05	0.000223	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	5.45e-05	0.000223	CcSEcCtD
Dasatinib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	5.43e-05	0.000223	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	5.43e-05	0.000223	CcSEcCtD
Dasatinib—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	5.41e-05	0.000222	CcSEcCtD
Dasatinib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	5.4e-05	0.000221	CcSEcCtD
Dasatinib—Chills—Epirubicin—peripheral nervous system neoplasm	5.37e-05	0.00022	CcSEcCtD
Dasatinib—Pruritus—Etoposide—peripheral nervous system neoplasm	5.37e-05	0.00022	CcSEcCtD
Dasatinib—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	5.35e-05	0.000219	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	5.34e-05	0.000219	CcSEcCtD
Dasatinib—Alopecia—Epirubicin—peripheral nervous system neoplasm	5.29e-05	0.000217	CcSEcCtD
Dasatinib—Vomiting—Cisplatin—peripheral nervous system neoplasm	5.27e-05	0.000216	CcSEcCtD
Dasatinib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	5.25e-05	0.000215	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	5.24e-05	0.000215	CcSEcCtD
Dasatinib—Rash—Cisplatin—peripheral nervous system neoplasm	5.22e-05	0.000214	CcSEcCtD
Dasatinib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	5.22e-05	0.000214	CcSEcCtD
Dasatinib—Erythema—Epirubicin—peripheral nervous system neoplasm	5.21e-05	0.000214	CcSEcCtD
Dasatinib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	5.21e-05	0.000214	CcSEcCtD
Dasatinib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	5.19e-05	0.000213	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	5.18e-05	0.000212	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	5.17e-05	0.000212	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—peripheral nervous system neoplasm	5.14e-05	0.000211	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	5.14e-05	0.000211	CcSEcCtD
Dasatinib—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	5.11e-05	0.000209	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	5.03e-05	0.000206	CcSEcCtD
Dasatinib—Dizziness—Etoposide—peripheral nervous system neoplasm	5.02e-05	0.000206	CcSEcCtD
Dasatinib—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	5.01e-05	0.000205	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	5.01e-05	0.000205	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	4.99e-05	0.000205	CcSEcCtD
Dasatinib—Chills—Doxorubicin—peripheral nervous system neoplasm	4.97e-05	0.000204	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	4.95e-05	0.000203	CcSEcCtD
Dasatinib—Nausea—Cisplatin—peripheral nervous system neoplasm	4.92e-05	0.000202	CcSEcCtD
Dasatinib—Vision blurred—Epirubicin—peripheral nervous system neoplasm	4.91e-05	0.000201	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	4.9e-05	0.000201	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	4.85e-05	0.000199	CcSEcCtD
Dasatinib—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	4.84e-05	0.000198	CcSEcCtD
Dasatinib—Vomiting—Etoposide—peripheral nervous system neoplasm	4.83e-05	0.000198	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	4.82e-05	0.000198	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—peripheral nervous system neoplasm	4.82e-05	0.000198	CcSEcCtD
Dasatinib—Anaemia—Epirubicin—peripheral nervous system neoplasm	4.82e-05	0.000197	CcSEcCtD
Dasatinib—Rash—Etoposide—peripheral nervous system neoplasm	4.79e-05	0.000196	CcSEcCtD
Dasatinib—Dermatitis—Etoposide—peripheral nervous system neoplasm	4.78e-05	0.000196	CcSEcCtD
Dasatinib—Headache—Etoposide—peripheral nervous system neoplasm	4.76e-05	0.000195	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	4.72e-05	0.000194	CcSEcCtD
Dasatinib—Malaise—Epirubicin—peripheral nervous system neoplasm	4.7e-05	0.000193	CcSEcCtD
Dasatinib—Vertigo—Epirubicin—peripheral nervous system neoplasm	4.68e-05	0.000192	CcSEcCtD
Dasatinib—Syncope—Epirubicin—peripheral nervous system neoplasm	4.68e-05	0.000192	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	4.64e-05	0.00019	CcSEcCtD
Dasatinib—Palpitations—Epirubicin—peripheral nervous system neoplasm	4.61e-05	0.000189	CcSEcCtD
Dasatinib—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	4.58e-05	0.000188	CcSEcCtD
Dasatinib—Cough—Epirubicin—peripheral nervous system neoplasm	4.55e-05	0.000186	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	4.55e-05	0.000186	CcSEcCtD
Dasatinib—Convulsion—Epirubicin—peripheral nervous system neoplasm	4.52e-05	0.000185	CcSEcCtD
Dasatinib—Nausea—Etoposide—peripheral nervous system neoplasm	4.51e-05	0.000185	CcSEcCtD
Dasatinib—Hypertension—Epirubicin—peripheral nervous system neoplasm	4.5e-05	0.000184	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	4.48e-05	0.000183	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	4.46e-05	0.000183	CcSEcCtD
Dasatinib—Myalgia—Epirubicin—peripheral nervous system neoplasm	4.44e-05	0.000182	CcSEcCtD
Dasatinib—Chest pain—Epirubicin—peripheral nervous system neoplasm	4.44e-05	0.000182	CcSEcCtD
Dasatinib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	4.44e-05	0.000182	CcSEcCtD
Dasatinib—Anxiety—Epirubicin—peripheral nervous system neoplasm	4.42e-05	0.000181	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	4.41e-05	0.000181	CcSEcCtD
Dasatinib—Discomfort—Epirubicin—peripheral nervous system neoplasm	4.39e-05	0.00018	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—peripheral nervous system neoplasm	4.35e-05	0.000178	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—peripheral nervous system neoplasm	4.33e-05	0.000178	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—peripheral nervous system neoplasm	4.33e-05	0.000177	CcSEcCtD
Dasatinib—Confusional state—Epirubicin—peripheral nervous system neoplasm	4.29e-05	0.000176	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—peripheral nervous system neoplasm	4.26e-05	0.000175	CcSEcCtD
Dasatinib—Oedema—Epirubicin—peripheral nervous system neoplasm	4.26e-05	0.000174	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	4.24e-05	0.000174	CcSEcCtD
Dasatinib—Infection—Epirubicin—peripheral nervous system neoplasm	4.23e-05	0.000173	CcSEcCtD
Dasatinib—Cough—Doxorubicin—peripheral nervous system neoplasm	4.21e-05	0.000173	CcSEcCtD
Dasatinib—Shock—Epirubicin—peripheral nervous system neoplasm	4.19e-05	0.000172	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—peripheral nervous system neoplasm	4.18e-05	0.000171	CcSEcCtD
Dasatinib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	4.17e-05	0.000171	CcSEcCtD
Dasatinib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	4.17e-05	0.000171	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—peripheral nervous system neoplasm	4.16e-05	0.000171	CcSEcCtD
Dasatinib—Tachycardia—Epirubicin—peripheral nervous system neoplasm	4.15e-05	0.00017	CcSEcCtD
Dasatinib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	4.13e-05	0.000169	CcSEcCtD
Dasatinib—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	4.11e-05	0.000169	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—peripheral nervous system neoplasm	4.11e-05	0.000168	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	4.11e-05	0.000168	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—peripheral nervous system neoplasm	4.11e-05	0.000168	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—peripheral nervous system neoplasm	4.09e-05	0.000168	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	4.08e-05	0.000167	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—peripheral nervous system neoplasm	4.06e-05	0.000166	CcSEcCtD
Dasatinib—Anorexia—Epirubicin—peripheral nervous system neoplasm	4.06e-05	0.000166	CcSEcCtD
Dasatinib—Hypotension—Epirubicin—peripheral nervous system neoplasm	3.98e-05	0.000163	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—peripheral nervous system neoplasm	3.97e-05	0.000163	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—peripheral nervous system neoplasm	3.94e-05	0.000161	CcSEcCtD
Dasatinib—Infection—Doxorubicin—peripheral nervous system neoplasm	3.91e-05	0.00016	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	3.88e-05	0.000159	CcSEcCtD
Dasatinib—Shock—Doxorubicin—peripheral nervous system neoplasm	3.87e-05	0.000159	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	3.86e-05	0.000158	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	3.85e-05	0.000158	CcSEcCtD
Dasatinib—Insomnia—Epirubicin—peripheral nervous system neoplasm	3.85e-05	0.000158	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	3.84e-05	0.000157	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.000157	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	3.81e-05	0.000156	CcSEcCtD
Dasatinib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	3.79e-05	0.000155	CcSEcCtD
Dasatinib—Somnolence—Epirubicin—peripheral nervous system neoplasm	3.78e-05	0.000155	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—peripheral nervous system neoplasm	3.75e-05	0.000154	CcSEcCtD
Dasatinib—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	3.75e-05	0.000153	CcSEcCtD
Dasatinib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	3.7e-05	0.000152	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—peripheral nervous system neoplasm	3.68e-05	0.000151	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	3.67e-05	0.000151	CcSEcCtD
Dasatinib—Fatigue—Epirubicin—peripheral nervous system neoplasm	3.67e-05	0.00015	CcSEcCtD
Dasatinib—Pain—Epirubicin—peripheral nervous system neoplasm	3.64e-05	0.000149	CcSEcCtD
Dasatinib—Constipation—Epirubicin—peripheral nervous system neoplasm	3.64e-05	0.000149	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	3.59e-05	0.000147	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	3.56e-05	0.000146	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	3.51e-05	0.000144	CcSEcCtD
Dasatinib—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	3.51e-05	0.000144	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—peripheral nervous system neoplasm	3.5e-05	0.000143	CcSEcCtD
Dasatinib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	3.48e-05	0.000143	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	3.47e-05	0.000142	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	3.42e-05	0.00014	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.4e-05	0.000139	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	3.39e-05	0.000139	CcSEcCtD
Dasatinib—Urticaria—Epirubicin—peripheral nervous system neoplasm	3.38e-05	0.000139	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—peripheral nervous system neoplasm	3.37e-05	0.000138	CcSEcCtD
Dasatinib—Pain—Doxorubicin—peripheral nervous system neoplasm	3.37e-05	0.000138	CcSEcCtD
Dasatinib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	3.36e-05	0.000138	CcSEcCtD
Dasatinib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	3.36e-05	0.000138	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	3.24e-05	0.000133	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	3.22e-05	0.000132	CcSEcCtD
Dasatinib—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	3.13e-05	0.000128	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—peripheral nervous system neoplasm	3.13e-05	0.000128	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	3.11e-05	0.000128	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	3.11e-05	0.000128	CcSEcCtD
Dasatinib—Asthenia—Epirubicin—peripheral nervous system neoplasm	3.05e-05	0.000125	CcSEcCtD
Dasatinib—Pruritus—Epirubicin—peripheral nervous system neoplasm	3.01e-05	0.000123	CcSEcCtD
Dasatinib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	2.91e-05	0.000119	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	2.9e-05	0.000119	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	2.82e-05	0.000116	CcSEcCtD
Dasatinib—Dizziness—Epirubicin—peripheral nervous system neoplasm	2.81e-05	0.000115	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	2.79e-05	0.000114	CcSEcCtD
Dasatinib—Vomiting—Epirubicin—peripheral nervous system neoplasm	2.71e-05	0.000111	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	2.69e-05	0.00011	CcSEcCtD
Dasatinib—Rash—Epirubicin—peripheral nervous system neoplasm	2.68e-05	0.00011	CcSEcCtD
Dasatinib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	2.68e-05	0.00011	CcSEcCtD
Dasatinib—Headache—Epirubicin—peripheral nervous system neoplasm	2.67e-05	0.000109	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	2.6e-05	0.000107	CcSEcCtD
Dasatinib—Nausea—Epirubicin—peripheral nervous system neoplasm	2.53e-05	0.000104	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	2.5e-05	0.000103	CcSEcCtD
Dasatinib—Rash—Doxorubicin—peripheral nervous system neoplasm	2.48e-05	0.000102	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.48e-05	0.000102	CcSEcCtD
Dasatinib—Headache—Doxorubicin—peripheral nervous system neoplasm	2.47e-05	0.000101	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.34e-05	9.58e-05	CcSEcCtD
Dasatinib—FYN—Hemostasis—AKT1—peripheral nervous system neoplasm	4.32e-06	2.14e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	4.3e-06	2.13e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—PTPN11—peripheral nervous system neoplasm	4.29e-06	2.13e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	4.29e-06	2.13e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—NRAS—peripheral nervous system neoplasm	4.26e-06	2.11e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	4.26e-06	2.11e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—peripheral nervous system neoplasm	4.25e-06	2.11e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—ERBB2—peripheral nervous system neoplasm	4.25e-06	2.11e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	4.25e-06	2.1e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—HRAS—peripheral nervous system neoplasm	4.24e-06	2.1e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—AKT1—peripheral nervous system neoplasm	4.24e-06	2.1e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—AKT1—peripheral nervous system neoplasm	4.23e-06	2.09e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	4.23e-06	2.09e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.22e-06	2.09e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.19e-06	2.08e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—HRAS—peripheral nervous system neoplasm	4.18e-06	2.07e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—AKT1—peripheral nervous system neoplasm	4.18e-06	2.07e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—AKT1—peripheral nervous system neoplasm	4.16e-06	2.06e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	4.1e-06	2.03e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—AKT1—peripheral nervous system neoplasm	4.1e-06	2.03e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	4.09e-06	2.03e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.09e-06	2.02e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—HRAS—peripheral nervous system neoplasm	4.07e-06	2.02e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.06e-06	2.01e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—ERBB2—peripheral nervous system neoplasm	4.04e-06	2e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.03e-06	2e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—NRAS—peripheral nervous system neoplasm	4.03e-06	2e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—AKT1—peripheral nervous system neoplasm	4.03e-06	2e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4e-06	1.98e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.99e-06	1.97e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—AKT1—peripheral nervous system neoplasm	3.98e-06	1.97e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—HRAS—peripheral nervous system neoplasm	3.98e-06	1.97e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—PTPN11—peripheral nervous system neoplasm	3.96e-06	1.96e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—AKT1—peripheral nervous system neoplasm	3.95e-06	1.95e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—NRAS—peripheral nervous system neoplasm	3.93e-06	1.95e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—AKT1—peripheral nervous system neoplasm	3.93e-06	1.95e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.91e-06	1.94e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.91e-06	1.93e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—AKT1—peripheral nervous system neoplasm	3.9e-06	1.93e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—AKT1—peripheral nervous system neoplasm	3.89e-06	1.92e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	3.87e-06	1.92e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—ERBB2—peripheral nervous system neoplasm	3.83e-06	1.9e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—AKT1—peripheral nervous system neoplasm	3.83e-06	1.9e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.83e-06	1.89e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—AKT1—peripheral nervous system neoplasm	3.82e-06	1.89e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	3.79e-06	1.88e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.77e-06	1.87e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—peripheral nervous system neoplasm	3.77e-06	1.87e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	3.75e-06	1.86e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—AKT1—peripheral nervous system neoplasm	3.74e-06	1.85e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	3.73e-06	1.85e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—NRAS—peripheral nervous system neoplasm	3.72e-06	1.84e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.71e-06	1.84e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—AKT1—peripheral nervous system neoplasm	3.69e-06	1.83e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	3.68e-06	1.82e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.68e-06	1.82e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	3.68e-06	1.82e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—HRAS—peripheral nervous system neoplasm	3.67e-06	1.82e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—HRAS—peripheral nervous system neoplasm	3.67e-06	1.82e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—MYC—peripheral nervous system neoplasm	3.67e-06	1.82e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—HRAS—peripheral nervous system neoplasm	3.66e-06	1.81e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.65e-06	1.81e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.64e-06	1.8e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—NRAS—peripheral nervous system neoplasm	3.63e-06	1.8e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.63e-06	1.8e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.62e-06	1.79e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—HRAS—peripheral nervous system neoplasm	3.6e-06	1.78e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—AKT1—peripheral nervous system neoplasm	3.59e-06	1.78e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.58e-06	1.77e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.56e-06	1.76e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—NRAS—peripheral nervous system neoplasm	3.56e-06	1.76e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—NRAS—peripheral nervous system neoplasm	3.54e-06	1.75e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—ERBB2—peripheral nervous system neoplasm	3.54e-06	1.75e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—GNAS—peripheral nervous system neoplasm	3.54e-06	1.75e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	3.52e-06	1.74e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.51e-06	1.74e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.51e-06	1.74e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—AKT1—peripheral nervous system neoplasm	3.51e-06	1.74e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—NRAS—peripheral nervous system neoplasm	3.5e-06	1.73e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—HRAS—peripheral nervous system neoplasm	3.49e-06	1.73e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	3.48e-06	1.72e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ABCB1—peripheral nervous system neoplasm	3.47e-06	1.72e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—MYC—peripheral nervous system neoplasm	3.47e-06	1.72e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	3.46e-06	1.71e-05	CbGpPWpGaD
Dasatinib—FMO3—Metabolism—AKT1—peripheral nervous system neoplasm	3.46e-06	1.71e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.45e-06	1.71e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.43e-06	1.7e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.4e-06	1.68e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—ERBB2—peripheral nervous system neoplasm	3.39e-06	1.68e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—NRAS—peripheral nervous system neoplasm	3.37e-06	1.67e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—NRAS—peripheral nervous system neoplasm	3.36e-06	1.66e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—NRAS—peripheral nervous system neoplasm	3.33e-06	1.65e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.29e-06	1.63e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.27e-06	1.62e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—HRAS—peripheral nervous system neoplasm	3.24e-06	1.61e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—AKT1—peripheral nervous system neoplasm	3.24e-06	1.61e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—AKT1—peripheral nervous system neoplasm	3.24e-06	1.61e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—AKT1—peripheral nervous system neoplasm	3.23e-06	1.6e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—NRAS—peripheral nervous system neoplasm	3.23e-06	1.6e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—AKT1—peripheral nervous system neoplasm	3.18e-06	1.58e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.14e-06	1.55e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—ERBB2—peripheral nervous system neoplasm	3.13e-06	1.55e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—MYC—peripheral nervous system neoplasm	3.13e-06	1.55e-05	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—MYC—peripheral nervous system neoplasm	3.12e-06	1.55e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—HRAS—peripheral nervous system neoplasm	3.12e-06	1.54e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	3.11e-06	1.54e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.11e-06	1.54e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	3.11e-06	1.54e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.09e-06	1.53e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.09e-06	1.53e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—AKT1—peripheral nervous system neoplasm	3.08e-06	1.53e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—NRAS—peripheral nervous system neoplasm	3.07e-06	1.52e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.05e-06	1.51e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.02e-06	1.5e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—MYC—peripheral nervous system neoplasm	3.01e-06	1.49e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.98e-06	1.47e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—HRAS—peripheral nervous system neoplasm	2.95e-06	1.46e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	2.94e-06	1.46e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.92e-06	1.44e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—NRAS—peripheral nervous system neoplasm	2.92e-06	1.44e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—HRAS—peripheral nervous system neoplasm	2.88e-06	1.43e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.87e-06	1.42e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.87e-06	1.42e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—MYC—peripheral nervous system neoplasm	2.86e-06	1.42e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—AKT1—peripheral nervous system neoplasm	2.86e-06	1.42e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.83e-06	1.4e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	2.83e-06	1.4e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.8e-06	1.39e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.8e-06	1.39e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.79e-06	1.38e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.78e-06	1.37e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	2.76e-06	1.37e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.76e-06	1.36e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—AKT1—peripheral nervous system neoplasm	2.75e-06	1.36e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	2.75e-06	1.36e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.74e-06	1.36e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—HRAS—peripheral nervous system neoplasm	2.72e-06	1.35e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.7e-06	1.34e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—NRAS—peripheral nervous system neoplasm	2.69e-06	1.33e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.69e-06	1.33e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	2.69e-06	1.33e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.67e-06	1.32e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.67e-06	1.32e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—HRAS—peripheral nervous system neoplasm	2.66e-06	1.32e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.61e-06	1.29e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—AKT1—peripheral nervous system neoplasm	2.61e-06	1.29e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—HRAS—peripheral nervous system neoplasm	2.6e-06	1.29e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.6e-06	1.29e-05	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.59e-06	1.28e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HRAS—peripheral nervous system neoplasm	2.59e-06	1.28e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—NRAS—peripheral nervous system neoplasm	2.58e-06	1.28e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.58e-06	1.28e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.57e-06	1.27e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.57e-06	1.27e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.57e-06	1.27e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—HRAS—peripheral nervous system neoplasm	2.56e-06	1.27e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—AKT1—peripheral nervous system neoplasm	2.54e-06	1.26e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—MYC—peripheral nervous system neoplasm	2.51e-06	1.24e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.48e-06	1.23e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—peripheral nervous system neoplasm	2.47e-06	1.22e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—peripheral nervous system neoplasm	2.45e-06	1.22e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—peripheral nervous system neoplasm	2.44e-06	1.21e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.43e-06	1.2e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—peripheral nervous system neoplasm	2.41e-06	1.19e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—NRAS—peripheral nervous system neoplasm	2.38e-06	1.18e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—peripheral nervous system neoplasm	2.37e-06	1.17e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.36e-06	1.17e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.36e-06	1.17e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.35e-06	1.17e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.35e-06	1.16e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—peripheral nervous system neoplasm	2.35e-06	1.16e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.3e-06	1.14e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—peripheral nervous system neoplasm	2.3e-06	1.14e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—peripheral nervous system neoplasm	2.29e-06	1.13e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.27e-06	1.12e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	2.27e-06	1.12e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.26e-06	1.12e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—peripheral nervous system neoplasm	2.26e-06	1.12e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.26e-06	1.12e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	2.26e-06	1.12e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.25e-06	1.11e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—peripheral nervous system neoplasm	2.25e-06	1.11e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—peripheral nervous system neoplasm	2.22e-06	1.1e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	2.21e-06	1.1e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.19e-06	1.09e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.19e-06	1.08e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.18e-06	1.08e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—peripheral nervous system neoplasm	2.18e-06	1.08e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—peripheral nervous system neoplasm	2.17e-06	1.07e-05	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—peripheral nervous system neoplasm	2.17e-06	1.07e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.16e-06	1.07e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.15e-06	1.07e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—peripheral nervous system neoplasm	2.15e-06	1.07e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.14e-06	1.06e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—peripheral nervous system neoplasm	2.13e-06	1.06e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	2.13e-06	1.06e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.11e-06	1.04e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.11e-06	1.04e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—peripheral nervous system neoplasm	2.09e-06	1.03e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.03e-06	1.01e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.02e-06	9.98e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.01e-06	9.93e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—peripheral nervous system neoplasm	2e-06	9.88e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.99e-06	9.87e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.99e-06	9.86e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—peripheral nervous system neoplasm	1.99e-06	9.83e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—peripheral nervous system neoplasm	1.97e-06	9.76e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.91e-06	9.45e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—peripheral nervous system neoplasm	1.89e-06	9.35e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.89e-06	9.34e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—peripheral nervous system neoplasm	1.88e-06	9.33e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.8e-06	8.9e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.78e-06	8.81e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.76e-06	8.71e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.76e-06	8.7e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—peripheral nervous system neoplasm	1.74e-06	8.64e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.74e-06	8.62e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—peripheral nervous system neoplasm	1.74e-06	8.61e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.73e-06	8.58e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.72e-06	8.51e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.71e-06	8.46e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.68e-06	8.34e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.68e-06	8.33e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.67e-06	8.27e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.67e-06	8.26e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—peripheral nervous system neoplasm	1.67e-06	8.26e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.66e-06	8.21e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.65e-06	8.16e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.6e-06	7.9e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.58e-06	7.8e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.56e-06	7.7e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—peripheral nervous system neoplasm	1.55e-06	7.68e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—peripheral nervous system neoplasm	1.54e-06	7.63e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.52e-06	7.52e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.49e-06	7.36e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.46e-06	7.25e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.44e-06	7.14e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	1.41e-06	6.99e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.41e-06	6.98e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.39e-06	6.89e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.38e-06	6.83e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.28e-06	6.32e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.22e-06	6.05e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.22e-06	6.03e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.08e-06	5.34e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	1.01e-06	5.01e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—peripheral nervous system neoplasm	9.55e-07	4.73e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	7.63e-07	3.78e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	6.09e-07	3.02e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	4.7e-07	2.33e-06	CbGpPWpGaD
